Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from boosted protease inhibitors to raltegravir in HIV-infected women with hyperlipidemia
2013-001564-37Phase 2Terminated
- Sponsor
- AGMT
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by AGMT. Primary endpoints: Reduction in direct LDL cholesterol or total cholesterol / reduction of lipid-lowering agents at week 12 and Changes in lipids over time and at endpoint. Started Oct 2013; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-001564-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001564-37.